导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.65% | 518/4773 |
| 近一周 | -0.94% | 1987/5467 |
| 近一月 | 5.03% | 33/5421 |
| 近一季 | 8.97% | 210/5238 |
| 近半年 | 18.90% | 343/4931 |
| 近一年 | 23.91% | 311/4400 |
| 近两年 | 84.37% | 772/2954 |
| 近三年 | 110.21% | 122/2253 |
| 成立以来 | 56.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.65% 1489/4961 |
-0.11% 3250/5312 |
- - |
- - |
| 2025 | 32.27% 1188/4813 |
10.06% 347/3635 |
11.40% 186/4076 |
-0.61% 3933/4524 |
8.55% 240/4813 |
| 2024 | 36.99% 47/3463 |
3.80% 510/2808 |
14.97% 6/3014 |
4.08% 2907/3129 |
10.29% 280/3463 |
| 2023 | 0.56% 405/2656 |
-0.19% 1782/2280 |
6.87% 38/2385 |
-6.22% 1457/2515 |
0.53% 142/2655 |
| 2022 | 4.77% 21/2207 |
8.74% 14/1919 |
0.27% 1567/2016 |
-11.82% 592/2113 |
8.97% 245/2208 |
| 2021 | 3.87% 599/1822 |
13.28% 9/1255 |
-3.70% 1250/1330 |
-5.04% 766/1466 |
0.26% 1150/1822 |
| 2020 | -17.74% 1007/1250 |
-11.19% 822/1028 |
-3.82% 1040/1067 |
-16.24% 1137/1164 |
14.96% 241/1184 |
| 2019 | - - |
- - |
- - |
-4.63% 781/850 |
6.20% 643/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 泰康香港银行指数C VS. 长安沪深300非周期A(740101) |